Oncodrivers in Malignant Pleural Effusions Associated With Non-small Cell Lung Cancer: A Prospective Study.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04806412 |
Recruitment Status : Unknown
Verified May 2022 by Naestved Hospital.
Recruitment status was: Recruiting
First Posted : March 19, 2021
Last Update Posted : May 17, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Malignant Pleural Effusion Non-small Cell Lung Cancer | Diagnostic Test: meassurement of PD-L1, ALK, EGFR | Not Applicable |
The study is a prospective, non-randomized, cohort study of patients with pleural effusion. Participants will be recruited from patients referred to the Pleura Clinic or admitted at the ward at the Department of Respiratory Medicine, Næstved Hospital, Næstved or at the Department of Respiratory Medicine, Zealand University Hospital, Roskilde, which is the two regional centres for workup of pleural effusions. Patients will be referred from either general practice or other hospital departments.
Pleural fluids with cytology positive for NSCLC will be tested for oncodrivers (for squamous cell carcinomas (SCC): PD-L1, for adenocarcinomas (AC): PD-L1, ALK and EGFR).
Follow-up will be 8 weeks after inclusion.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 100 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Intervention Model Description: | prospective, non-randomized, cohort study |
Masking: | None (Open Label) |
Primary Purpose: | Diagnostic |
Official Title: | The Prevalence of Oncodrivers in Malignant Pleural Effusions Associated With Non-small Cell Lung Cancer: A Prospective Study. |
Actual Study Start Date : | March 15, 2021 |
Estimated Primary Completion Date : | March 12, 2023 |
Estimated Study Completion Date : | May 12, 2023 |
- Diagnostic Test: meassurement of PD-L1, ALK, EGFR
PD-L1 test will be performed on cell-blocks using PD-L1 antibodies 22C3 and staining platform Dako Omnis (Agilent, Glostrup -Denmark).
ALK test will be performed on cell-blocks using staining platform Dako Omnis (Agilent, Glostrup- Denmark) and ALK antibodies "Origene" clone: OT1A4. Sample quality is assessed as for PD-L1.
EGFR mutation analysis will be performed as follows: after tumor content evaluation of hematoxylin and eosin stained slides, relevant regions are macrodissected and subjected to a standard genomic DNA extraction procedure using the GeneRead DNA FFPE Kit (Qiagen). Samples will be analysed using the GeneRead QIAact Actionable Insights Tumor Panel (Qiagen)
- Prevalence of oncodriver status [ Time Frame: assessed at 8 weeks follow-up ]Prevalence of oncodriver status (for squamous cell carcinomas (SCC): PD-L1, for adenocarcinomas (AC): PD-L1, ALK and EGFR) in pleural fluid in patients with cytology positive for pulmonary NSCLC
- Proportion of adequate and inadequate pleural fluid specimens [ Time Frame: assessed at 8-week follow-up ]
- Amounts of pleural fluid sent for analysis [ Time Frame: assessed at 8-week follow-up ]Meassured in mL.
- Correlation between amounts of pleural fluid sent to the pathologist and the chance of obtaining oncodriver status [ Time Frame: assessed at 8-week follow-up ]
- Number and type of additional diagnostic interventions including additional thoracentesis and cytological or histological biopsies [ Time Frame: assessed at 8-week follow-up ]
- Prevalence of oncodriver status in additional diagnostic interventions [ Time Frame: assessed at 8-week follow-up ]
- - Correlation between oncodriver status obtained in pleural fluid specimens and cytological or histological biopsies [ Time Frame: assessed at 8-week follow-up ]
- - Proportion of work-ups where the lack of obtained oncodriver status in pleural fluid specimens leads to additional diagnostic interventions including additional thoracentesis and cytological or histological biopsies [ Time Frame: assessed at 8-week follow-up ]
- - Proportion of work-ups where full oncodriver-status was obtained at the second thoracentesis [ Time Frame: assessed at 8-week follow-up ]
- - Proportion of patients with pleural fluid cytology negative of NSCLC, who is diagnosed with NSCLC. [ Time Frame: assessed at 8-week follow-up ]
- Patient assessed pain during thoracentesis [ Time Frame: at day 1, 2 minutes after thoracentesis ]assessed by a questionnaire containing a VAS (Visual Analogue Scale, scale 0-10, 0 being no pain, 10 being the worse pain)
- Proportion of patients experiencing pneumothorax [ Time Frame: assessed at day 1, 10 minutes after thoracentesis and 8-week follow-up by evaluating the patient file ]
- Proportion of patients experiencing bleeding [ Time Frame: assessed at day 1, 10 minutes after thoracentesis and 8-week follow-up ]
- Proportion of complications leading to admission [ Time Frame: assessed at 8-week follow-up ]assessed by evaluating the patient file
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age ≥ 18 years
- Pleural effusion known or suspected of association with NSCLC (pleural fluid cytology positive for cells from NSCLC)
- Patients must be able to give informed consent
Exclusion Criteria:
- Full oncodriver status measured in any pleural fluid in current work-up
- Inability to understand written or spoken Danish.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04806412
Contact: Katrine Fjaellegaard, MD | 31924375 | kafj@regionsjaelland.dk |
Denmark | |
Næstved Sygehus, department of pulmonary medicine | Recruiting |
Næstved, Region Sjælland, Denmark, 4700 | |
Contact: katrine fjællegaard, MD 20864959 kafj@regionsjaelland.dk | |
Contact: Uffe Bødtger, MD, PhD |
Responsible Party: | Naestved Hospital |
ClinicalTrials.gov Identifier: | NCT04806412 |
Other Study ID Numbers: |
SJ-889 |
First Posted: | March 19, 2021 Key Record Dates |
Last Update Posted: | May 17, 2022 |
Last Verified: | May 2022 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Lung Neoplasms Carcinoma, Non-Small-Cell Lung Pleural Effusion, Malignant Pleural Effusion Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site |
Neoplasms Lung Diseases Respiratory Tract Diseases Carcinoma, Bronchogenic Bronchial Neoplasms Pleural Diseases Pleural Neoplasms |